Table 1.
Patient characteristics
| Age (year), median (range) | 72 (38–85) | ||
| Male/female | 15/6 | ||
| Colon/rectum | 16/5 | ||
| Lesion site/numbers | Liver | 1 | 10 |
| 2 | 1 | ||
| 3 | 1 | ||
| Lung | 1 | 6 | |
| 2 | 2 | ||
| 3 | 1 | ||
| Size of maximum diameter (mm), median (range) | 14 (5–50) | ||
| CEA level before SBRT | Normal (≤5 ng/ml) | 14 | |
| Slightly high (5–10 ng/ml) | 4 | ||
| High (≤10 ng/ml) | 3 | ||
| Interval between the initial treatment and SBRT, median (range) (months) | 30.1(5.1–83.8) | ||
| Follow-up duration from SBRT, median (range) (months) | 27.5(6.5–43.3) | ||
| Total dose (BED10 Gy) | 60 Gy/5 fr (132 Gy10) | 15 | |
| 50 Gy/5 fr (100 Gy10) | 13 | ||
| Usage of chemotherapy | Yes/no | 18/3 | |
| As an initial treatment | 15 | ||
| As a treatment for recurrence | 9 | ||
CEA, Carcinoembryonic antigen; SBRT, stereotactic body radiotherapy; BED, biological effective dose.